Cited 0 times in
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.contributor.author | 조재호 | - |
dc.date.accessioned | 2015-04-24T17:34:57Z | - |
dc.date.available | 2015-04-24T17:34:57Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/105674 | - |
dc.description.abstract | PURPOSE: On the basis of the benefits of frontline radiation in early-stage, extranodal, natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by three cycles of etoposide, ifosfamide, cisplatin, and dexamethasone (VIPD). PATIENTS AND METHODS: Thirty patients with newly diagnosed, stages IE to IIE, nasal ENKTL received CCRT (ie radiation 40 to 52.8 Gy and cisplatin 30 mg/m(2) weekly). Three cycles of VIPD (etoposide 100 mg/m(2) days 1 through 3, ifosfamide 1,200 mg/m(2) days 1 through 3, cisplatin 33 mg/m(2) days 1 through 3, and dexamethasone 40 mg days 1 through 4) were scheduled after CCRT. RESULTS: All patients completed CCRT, which resulted in 100% response that included 22 complete responses (CRs) and eight partial responses (PRs). The CR rate after CCRT was 73.3% (ie, 22 of 30 responses; 95% CI, 57.46 to 89.13). Twenty-six of 30 patients completed the planned three cycles of VIPD, whereas four patients did not because they withdrew (n = 2) or because they had an infection (n = 2). The overall response rate and the CR rate were 83.3% (ie; 25 of 30 responses; 95% CI, 65.28 to 94.36) and 80.0% (ie, 24 of 30 responses; 95% CI, 65.69 to 94.31), respectively. Only one patient experienced grade 3 toxicity during CCRT (nausea), whereas 12 of 29 patients experienced grade 4 neutropenia. The estimated 3-year, progression-free and overall survival rates were 85.19% (95% CI, 72.48 to 97.90) and 86.28% (95% CI, 73.97 to 98.59), respectively. CONCLUSION: Patients with newly diagnosed, stages IE to IIE, nasal ENKTL are best treated with frontline CCRT. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 6027~6032 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Dexamethasone/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Etoposide/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ifosfamide/administration & dosage | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Lymphoma, Extranodal NK-T-Cell/drug therapy* | - |
dc.subject.MESH | Lymphoma, Extranodal NK-T-Cell/mortality | - |
dc.subject.MESH | Lymphoma, Extranodal NK-T-Cell/pathology | - |
dc.subject.MESH | Lymphoma, Extranodal NK-T-Cell/radiotherapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Nose Neoplasms/drug therapy* | - |
dc.subject.MESH | Nose Neoplasms/mortality | - |
dc.subject.MESH | Nose Neoplasms/radiotherapy* | - |
dc.subject.MESH | Nose Neoplasms/secondary | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Radiotherapy, Adjuvant | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Byung Soo Kim | - |
dc.contributor.googleauthor | Chul Yong Kim | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Jooryung Huh | - |
dc.contributor.googleauthor | Sang-Wook Lee | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Jaeho Cho | - |
dc.contributor.googleauthor | Gyeong-Won Lee | - |
dc.contributor.googleauthor | Ki Mun Kang | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Hong Ryull Pyo | - |
dc.contributor.googleauthor | Yong Chan Ahn | - |
dc.contributor.googleauthor | Young Hyeh Ko | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.1200/JCO.2009.23.8592 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A03901 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 19884539 | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Cho, Jae Ho | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Cho, Jae Ho | - |
dc.citation.volume | 27 | - |
dc.citation.number | 35 | - |
dc.citation.startPage | 6027 | - |
dc.citation.endPage | 6032 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.27(35) : 6027-6032, 2009 | - |
dc.identifier.rimsid | 42657 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.